VitaNova Life Sciences (VNOV) Receivables (2024 - 2026)

VitaNova Life Sciences has reported Receivables for 3 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables changed N/A year-over-year to $1.0 million; the trailing twelve-month figure through Jan 2026 stood at $1.0 million (changed N/A YoY), and the FY2025 full-year result was $1.4 million, up 209.36% from the prior year.
• Receivables for Q1 2026 stood at $1.0 million, up from $882612.0 in the prior quarter.
• The five-year high for Receivables was $1.4 million in Q2 2025, with the low at $57700.0 in Q4 2024.
• Historically, Receivables has averaged $807609.8 across 3 years, with a median of $943527.0 in 2025.
• The largest YoY upside for Receivables was 1429.66% in 2025 against a maximum downside of 209.36% in 2025.
• VitaNova Life Sciences' Receivables stood at $57700.0 in 2024, then soared by 1429.66% to $882612.0 in 2025, then advanced by 13.8% to $1.0 million in 2026.
• The last three Receivables figures came in at $1.0 million (Q1 2026), $882612.0 (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.